BioCurex, Inc.(fka BOCX)

[opportunityknocking]

Taking into consideration that there are 100 million visits from new patients each year, we estimate a potential market size for RECAF "point-of-care" tests of 50 million determinations per year in the U.S.A. alone. The European Union and Japan combined have twice the population of the U.S.A. and therefore it is safe to assume that they represent another 100 million tests. Given the low cost of the test and the possibility that it might be the only RECAF test affordable in many regions, it seems reasonable to allocate another 50 million tests to China, India and the rest of the world. Assuming a price of $5 per test, the estimated potential market would therefore be approximately $1 billion per year.

Ka-ching. It's coming.